Caio M Massari Selected Research

N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamide

1/2020

Striatal Dopamine D2-Muscarinic Acetylcholine M1 Receptor-Receptor Interaction in a Model of Movement Disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caio M Massari Research Topics

Disease

2	Movement Disorders (Movement Disorder) 01/2020 - 01/2017
2	Catalepsy 01/2020 - 01/2017
2	Parkinson Disease (Parkinson's Disease) 01/2017 - 12/2016
1	Parkinsonian Disorders (Parkinsonism) 01/2020
1	Ischemia 12/2019
1	Dyskinesias (Dyskinesia) 01/2017
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2016
1	Hypercholesterolemia 12/2016

Drug/Important Bio-Agent (IBA)

3	Neuroprotective AgentsIBA 12/2019 - 12/2016
2	Reserpine (Serpasil)FDA Link 01/2020 - 01/2017
2	GuanosineIBA 12/2019 - 01/2017
2	Neurotransmitter Agents (Neurotransmitter)IBA 12/2019 - 12/2016
1	U 95666EIBA 01/2020
1	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 01/2020
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2020
1	Dopamine (Intropin)FDA LinkGeneric 01/2020
1	Purine NucleosidesIBA 12/2019
1	GuanineIBA 12/2019
1	Levodopa (L Dopa)FDA LinkGeneric 01/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2016
1	Oxidopamine (6 Hydroxydopamine)IBA 12/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2016